CryoPort, Inc. (CYRX)

CryoPort's stock price has been influenced by several events and financial trends in the past six months. Revenue growth in the Life Sciences Services segment has shown signs of slowing. The company's adjusted EBITDA margin has remained negative. Concerns exist regarding slowing demand and potential decline in cell and gene therapy approvals. Cryoport announced solid full-year 2024 revenue and improved gross margin. The company reported a strong start to 2025 with increased revenue and improved adjusted EBITDA. A new global supply chain center in Paris was announced. CryoPort has a consensus rating of "Moderate Buy" from analysts.

Information regarding the specific demand seasonality for CryoPort, Inc.'s products and services is not readily available. Specific seasonal trends in demand cannot be definitively stated based on the current public information.

CryoPort, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences industry, particularly cell and gene therapies. The company operates in the Healthcare sector, specifically in Biotechnology: Pharmaceutical Preparations, and Transportation, in the Integrated Freight & Logistics industry. CryoPort's business is divided into Life Sciences Services, offering temperature-controlled logistics and cryogenic biostorage, and Life Sciences Products, providing cryogenic freezers, dewars, and accessories.

CryoPort, Inc. has a significant global presence with 50 strategic locations across the Americas, EMEA, and APAC. The company expanded its footprint with a new Global Supply Chain Center in Louvres, France, near Paris Charles de Gaulle Airport, to support complex life sciences supply chain needs.

CryoPort has received positive recognition for its innovation, including the 2025 BioTech Breakthrough Award for "BioServices Innovation of the Year." Analyst sentiment is generally positive, with a consensus rating of "Moderate Buy." However, some financial analyses have highlighted concerns about the company's fundamentals, profitability, and cash flow challenges, which could indirectly affect its reputation among investors.

CryoPort, Inc. has significant institutional ownership, with 319 institutional owners holding a substantial percentage of the stock. Individual insiders hold a smaller percentage of shares. In the past three months, CryoPort insiders have sold more company stock than they have bought.